Predict your next investment

Corporation
HEALTHCARE | Medical Facilities & Services / Medical Laboratories & Research
microbiomelabs.com

See what CB Insights has to offer

Investments

1

About Microbiome Labs

Microbiome Labs is a research lab and supplements company that specializes in probiotics and gut health.On December 18th, 2020, Microbiome Labs was acquired by Novozymes at a valuation of $90.71M.

Microbiome Labs Headquarter Location

101 E Town Place Suite 210

Saint Augustine, Florida, 32092,

United States

904-940-2208

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Microbiome Labs Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Microbiome Labs Rank

Latest Microbiome Labs News

Global Human Microbiome Market to Surpass US$ 306,351.2 Million by 2028, Says Coherent Market Insights (CMI)

Jun 3, 2021

Pune, INDIA SEATTLE, June 03, 2021 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global human microbiome market is estimated to be valued at US$ 91,075.4 million in 2021 and is expected to exhibit a CAGR of 18.9% during the forecast period (2021-2028). Key Trends and Analysis of the Global Human Microbiome Market : Key trends in the market include increasing research and development activities, inorganic activities such as acquisition, increasing prevalence in various gut disorders (IBD, Crohn’s disease etc. ), product launches, and others. Market players are indulged in launching new products, which is expected to drive the growth of the market over the forecast period. For instance, on January 28, 2021, HempFusion Wellness Inc. launched its Total Care Immune probiotic product in the U.S. The product is the combination of the daily digestives and immune support of pre-, pro- and post-biotics with the immune-supporting power of elderberry. Request for Sample copy of this Report @ https://www.coherentmarketinsights.com/market-insight/human-microbiome-market-182 Market players are engaged in research and development activities, which is expected to increase the growth of the global human microbiome market. On January 7, 2021 Seres Therapeutics published positive data analyses from its Phase Ib trial of oral biologically derived microbiome therapeutic candidate, SER-287, in patients with active mild-to-moderate ulcerative colitis (UC). Moreover, on August 10, 2020, Seres Therapeutics, Inc. reported positive topline results from the pivotal Phase III ECOSPOR III study, which evaluated its investigational oral microbiome therapeutic SER-109 for recurrent Clostridium difficile infection (CDI). Key players are indulged in inorganic activities, such as acquisition, in order to expand their product portfolio, which is expected to increase the growth of the market over the forecast period. In 2020, Novozymes acquired Microbiome Labs, a developer of probiotic and microbiome solutions. Post-acquisition, Novozymes created a strong position in the North American probiotics market. Key Market Takeaways: Increasing popularity of microbiome-based food is expected to increase the growth of the global human microbiome market over the forecast period. For instance, in October 2020, Yakult Honsha Co. Ltd., which is a world leader in probiotic drinks, announced its plans to sell 485,000 thousands bottles of Yakult 400W per day in Japan, from October 2020 to March 2021. The company recently received the Food with Function Claim (FFC) label in Japan. Among regions, North America is expected to hold a dominant position in the global human microbiome market over the forecast period, owing to increasing incidence rate of various gut disorders (IBD, Crohn’s disease etc.) For instance, according to the Journal of Gastroenterology’s on Inflammatory Bowel Disease (IBD), in 2019, around 1.6 million patients in the U.S. suffered from IBD, out of which a considerable section belonged to Crohn’s disease patients and about 907,000 of the patients suffered from ulcerative colitis. Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/182 Competitive Landscape: Key players operating in the global human microbiome market include ENTEROME SA, Embion Technologies S.A, IGEN BIOLAB GROUP, Evelo Biosciences Inc., Ferring Pharmaceuticals, 4D Pharma Plc., Gnubiotics Sciences, YSOPIA Bioscience, ViThera Pharmaceuticals Inc., SECOND GENOME THERAPEUTICS, Osel Inc., OxThera AB, Immuron Ltd., AOBiome, Vedanta Biosciences, Inc., Rebiotix Inc., Seres Therapeutics, Inc., Assembly Biosciences, Inc., and Finch Therapeutics Group, Inc. Market Segmentation: Foods Clostridium Difficile Infection (CDI) Hospital Pharmacies North America

Microbiome Labs Investments

1 Investments

Microbiome Labs has made 1 investments. Their latest investment was in M Kombucha as part of their Seed on March 3, 2020.

CBI Logo

Microbiome Labs Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

3/31/2020

Seed

M Kombucha

Yes

1

Date

3/31/2020

Round

Seed

Company

M Kombucha

Amount

New?

Yes

Co-Investors

Sources

1

Microbiome Labs Team

1 Team Member

Microbiome Labs has 1 team member, including current President, Tom Bayne.

Name

Work History

Title

Status

Tom Bayne

President

Current

Name

Tom Bayne

Work History

Title

President

Status

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.